第1页å‚è§é™„ä»¶(2036KB,3页)。
[摘è¦] 目的 ç ”ç©¶survivin与p16 蛋白在胃癌组织åŠèƒƒç™Œç™Œå‰ç—…å˜ç»„织ä¸çš„è¡¨è¾¾åŠæ„义。方法 60例胃癌患者的胃癌组织,20ä¾‹ç™Œæ—æ£å¸¸ç»„织,30例胃镜活检的癌å‰ç—…å˜èƒƒç»„织,采用å…疫组织化å¦SP法检测的survivin与p16蛋白的表达情况。结果 survivin蛋白和p16蛋白在胃癌组织ã€ç™Œå‰ç—…å˜ç»„ç»‡ã€æ£å¸¸èƒƒç»„织ä¸å·®å¼‚æœ‰ç»Ÿè®¡å¦æ„义(p0.05)ï¼Œè€Œä¸Žä¸´åºŠåˆ†æœŸã€æ·‹å·´ç»“转移情况相关(p0.05);In the gastric carcinoma survivin had no significant relationship with histological differentiation grade. Significant relationship was found between survivin expression and TNM stage,lymph node metastiasis of gastric carcinoma. In the gastric carcinoma p16 expression had significant relationship with histological differentiation grade,TNM stage and lymph node metastiasis.conclusion Survivin and P16 participate in the abnormal expression of gastric cancer invasion and metastasis process, they are likely to determine the biological behavior of gastric cancer and the prognosis important factor.
ä¸å›¾åˆ†ç±»å·ï¼šR735.2æ–‡çŒ®æ ‡è¯†ç :B æ–‡ç« ç¼–å·ï¼š1004-7484(2011)05-0004-03
胃癌的å‘生å‘å±•ä¸Žç™ŒåŸºå› çš„æ¿€æ´»ã€æŠ‘ç™ŒåŸºå› çš„å¤±è¡¨è¾¾ä»¥åŠç»†èƒžçš„凋亡失衡ç‰ç›¸å…³ã€‚SurvivinåŸºå› æ˜¯å‡‹äº¡æŠ‘åˆ¶åŸºå› çš„æ–°æˆå‘˜ï¼Œé«˜è¡¨è¾¾äºŽå¤šç§è‚¿ç˜¤ç»„织和转化细胞。我们采用å…疫组化技术SP法,检测胃癌组织åŠç™Œæ—组织ä¸survivin与p16蛋白的表达情况,并对相应结果进行统计å¦åˆ†æžå’ŒæŽ¢è®¨ã€‚
1 ææ–™ä¸Žæ–¹æ³•
1.1 ææ–™æ”¶é›†ï¼š
选自2009-1-2010-6æ½åŠäººæ°‘医院胃癌组织60例,其ä¸ç”·æ€§45例,女性15例,平å‡å¹´é¾„65.3å²ï¼Œèƒƒé•œèŽ·å–的异型增生胃粘膜30例,男性21例,女性9例,平å‡å¹´é¾„50.1å²ï¼Œé€‰å–è·ç¦»èƒƒç™Œç»„织边缘大于5cm且病ç†è¯å®žæ— 肿瘤细胞侵犯的æ£å¸¸èƒƒç²˜è†œç»„织20ä¾‹ä½œä¸ºé˜´æ€§å¯¹ç…§ã€‚èƒƒç™Œæ‚£è€…æœ¯å‰æœªè¿›è¡Œæ”¾ç–—æˆ–åŒ–ç–—ã€‚æ ¹æ®å›½é™…抗癌è”盟(UICC)关于胃癌TNMåˆ†æœŸæ–¹æ³•è¿›è¡Œä¸´åºŠåˆ†æœŸï¼šâ… æœŸ17例,Ⅱ期21例,Ⅲ期22例;高分化腺癌8例,ä¸åˆ†åŒ–腺癌22例,低分化腺癌30例;转移情况:å‘生淋巴结转移者46ä¾‹ï¼Œæ— æ·‹å·´è½¬ç§»è€…14例。
1.2 试剂与方法:
Survivin兔抗人多克隆抗体和p16é¼ æŠ—äººå•克隆抗体工作液,å‡è´è‡ªåŒ—äº¬ä¸æ‰é‡‘桥公å¸ã€‚æ“作按照说明书æ¥éª¤è¿›è¡Œï¼Œä»¥å·²çŸ¥é˜³æ€§èƒƒç™Œåˆ‡ç‰‡ä½œä¸ºé˜³æ€§å¯¹ç…§ã€‚
1.3 æ ‡æœ¬å¤„ç†ï¼š
æ ‡æœ¬å¸¸è§„è„±èœ¡æ°´åŒ–åŽç»3%过氧化氢处ç†ï¼Œå¾®æ³¢æŠ—原修å¤ï¼Œå…¶å®ƒæŸ“色æ¥éª¤æŒ‰è¯•剂说明书进行。
1.4 é˜³æ€§æ ‡å‡†ï¼š
å…ç–«ç»„åŒ–æŸ“è‰²é˜³æ€§æ ‡å¿—ä¸ºç»†èƒžå†…å‡ºçŽ°é»„è‡³æ£•é»„è‰²é¢—ç²’ ......
